Stockreport

Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet

Intercept Pharmaceuticals, Inc.  (ICPT) 
Last intercept pharmaceuticals, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.interceptpharma.com/investor-relations
PDF NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization [Read more]